title: Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, The Netherlands. gelderblom@onch.azr.nl
authors.forename: A J
authors.initials: AJ
authors.lastname: Gelderblom
authors.forename: W J
authors.initials: WJ
authors.lastname: Loos
authors.forename: M J
authors.initials: MJ
authors.lastname: de Jonge
authors.forename: A
authors.initials: A
authors.lastname: Sparreboom
authors.forename: A S
authors.initials: AS
authors.lastname: Planting
authors.forename: M E
authors.initials: ME
authors.lastname: van der Burg
authors.forename: E
authors.initials: E
authors.lastname: Brouwer
authors.forename: C
authors.initials: C
authors.lastname: Verheij
authors.forename: L
authors.initials: L
authors.lastname: Ouwens
authors.forename: S
authors.initials: S
authors.lastname: Hearn
authors.forename: J
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D019772:Topotecan; D002945:Cisplatin